{"symbol":"BSX","fiscalQuarter":"Q2-2017","reportDate":"2017-07-27","reportTime":"BMO","status":"reported","company":{"name":"Boston Scientific Corporation","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BSX/earnings/Q2-2017","postBrief":{"headline":"Boston Scientific Beats on EPS, Stock Down 1.35%","keyNumbers":[{"metric":"EPS","actual":"$0.32","expected":"N/A","surprise":"+2.84%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing product innovation as a key driver for future growth.","They acknowledged challenges in certain markets but expressed confidence in their long-term strategy."],"summary":"Overall, management remains positive about the company's direction despite some market challenges. They emphasized their commitment to innovation and growth."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Boston Scientific's earnings report shows a slight beat on EPS, indicating better-than-expected profitability. However, the stock fell by 1.35%, likely due to a lack of revenue data and no guidance updates, which may have left investors uncertain about future performance. The company's focus on innovation suggests potential for growth, but market challenges remain a concern.","metaDescription":"Boston Scientific (BSX) Q2 2017 earnings: EPS beat by 2.84%. Stock down 1.35%. Full breakdown."}}